Antacid Treatment of Duodenal Ulcer

ULRIK BECKER*, KAREN LINDORFF, CARSTEN ANDERSEN, POUL JØRGEN RANLØV

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

ABSTRACT. Becker U, Lindorff K, Andersen C, Ranløv PJ (Department of Internal Medicine B, Central Hospital, Hillerød, Denmark). Antacid treatment of duodenal ulcer. Acta Med Scand 1987; 221:95–101. Sixty‐seven consecutive outpatients with endoscopically verified duodenal ulcer were randomised to a double‐blind treatment with either 10 ml of an antacid suspension (buffering capacity 85 mmol/10 ml, packed in single dosage pads) 1 and 3 h after each meal and at bedtime or cimetidine 400 mg b.i.d. The double‐dummy technique was employed. Endoscopy was performed after 4 weeks treatment and, if the ulcer had not healed, after 8 weeks treatment. When ulcer healing had occurred, the patient entered a 1 year follow‐up study. The cumulative healing rates after 4 and 8 weeks treatment were 83 and 97% vs. 69 and 94% in the antacid and cimetidine groups respectively. No significant differences were observed between the treatment groups regarding ulcer healing, symptom relief or compliance. Adverse reactions were few and only 3 (9%) patients in the antacid group had to discontinue the treatment due to diarrhoea. Of the cimetidine treated patients, 61% had symptomatic relapse during the 1 year follow‐up compared to 71% of the antacid treated patients. There were no significant differences in recurrence rate or time to relapse. The moderate dose antacid treatment used here is efficient, well tolerated, safe, convenient and is a good alternative treatment of the duodenal ulcer patient. 1987 Association for the Publication of the Journal of Internal Medicine

OriginalsprogEngelsk
TidsskriftACTA MEDICA SCANDINAVICA
Vol/bind221
Udgave nummer1
Sider (fra-til)95-101
Antal sider7
ISSN0001-6101
DOI
StatusUdgivet - 1. jan. 1987

Fingeraftryk

Duodenal Ulcer
Cimetidine
Ulcer
Internal Medicine
Denmark
Compliance
Meals
Publications
Outpatients

Citer dette

BECKER, ULRIK., LINDORFF, KAREN., ANDERSEN, CARSTEN., & RANLØV, POUL. JØRGEN. (1987). Antacid Treatment of Duodenal Ulcer. ACTA MEDICA SCANDINAVICA, 221(1), 95-101. https://doi.org/10.1111/j.0954-6820.1987.tb01249.x
BECKER, ULRIK ; LINDORFF, KAREN ; ANDERSEN, CARSTEN ; RANLØV, POUL JØRGEN. / Antacid Treatment of Duodenal Ulcer. I: ACTA MEDICA SCANDINAVICA. 1987 ; Bind 221, Nr. 1. s. 95-101.
@article{2ae22b32977f4dc98285dc02d37f81da,
title = "Antacid Treatment of Duodenal Ulcer",
abstract = "ABSTRACT. Becker U, Lindorff K, Andersen C, Ranl{\o}v PJ (Department of Internal Medicine B, Central Hospital, Hiller{\o}d, Denmark). Antacid treatment of duodenal ulcer. Acta Med Scand 1987; 221:95–101. Sixty‐seven consecutive outpatients with endoscopically verified duodenal ulcer were randomised to a double‐blind treatment with either 10 ml of an antacid suspension (buffering capacity 85 mmol/10 ml, packed in single dosage pads) 1 and 3 h after each meal and at bedtime or cimetidine 400 mg b.i.d. The double‐dummy technique was employed. Endoscopy was performed after 4 weeks treatment and, if the ulcer had not healed, after 8 weeks treatment. When ulcer healing had occurred, the patient entered a 1 year follow‐up study. The cumulative healing rates after 4 and 8 weeks treatment were 83 and 97{\%} vs. 69 and 94{\%} in the antacid and cimetidine groups respectively. No significant differences were observed between the treatment groups regarding ulcer healing, symptom relief or compliance. Adverse reactions were few and only 3 (9{\%}) patients in the antacid group had to discontinue the treatment due to diarrhoea. Of the cimetidine treated patients, 61{\%} had symptomatic relapse during the 1 year follow‐up compared to 71{\%} of the antacid treated patients. There were no significant differences in recurrence rate or time to relapse. The moderate dose antacid treatment used here is efficient, well tolerated, safe, convenient and is a good alternative treatment of the duodenal ulcer patient. 1987 Association for the Publication of the Journal of Internal Medicine",
keywords = "antacid, cimetidine, duodenai ulcer, healing, relapse",
author = "ULRIK BECKER and KAREN LINDORFF and CARSTEN ANDERSEN and RANL{\O}V, {POUL J{\O}RGEN}",
year = "1987",
month = "1",
day = "1",
doi = "10.1111/j.0954-6820.1987.tb01249.x",
language = "English",
volume = "221",
pages = "95--101",
journal = "ACTA MEDICA SCANDINAVICA",
issn = "0001-6101",
publisher = "Egyetem",
number = "1",

}

BECKER, ULRIK, LINDORFF, KAREN, ANDERSEN, CARSTEN & RANLØV, POULJØRGEN 1987, 'Antacid Treatment of Duodenal Ulcer', ACTA MEDICA SCANDINAVICA, bind 221, nr. 1, s. 95-101. https://doi.org/10.1111/j.0954-6820.1987.tb01249.x

Antacid Treatment of Duodenal Ulcer. / BECKER, ULRIK; LINDORFF, KAREN; ANDERSEN, CARSTEN; RANLØV, POUL JØRGEN.

I: ACTA MEDICA SCANDINAVICA, Bind 221, Nr. 1, 01.01.1987, s. 95-101.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Antacid Treatment of Duodenal Ulcer

AU - BECKER, ULRIK

AU - LINDORFF, KAREN

AU - ANDERSEN, CARSTEN

AU - RANLØV, POUL JØRGEN

PY - 1987/1/1

Y1 - 1987/1/1

N2 - ABSTRACT. Becker U, Lindorff K, Andersen C, Ranløv PJ (Department of Internal Medicine B, Central Hospital, Hillerød, Denmark). Antacid treatment of duodenal ulcer. Acta Med Scand 1987; 221:95–101. Sixty‐seven consecutive outpatients with endoscopically verified duodenal ulcer were randomised to a double‐blind treatment with either 10 ml of an antacid suspension (buffering capacity 85 mmol/10 ml, packed in single dosage pads) 1 and 3 h after each meal and at bedtime or cimetidine 400 mg b.i.d. The double‐dummy technique was employed. Endoscopy was performed after 4 weeks treatment and, if the ulcer had not healed, after 8 weeks treatment. When ulcer healing had occurred, the patient entered a 1 year follow‐up study. The cumulative healing rates after 4 and 8 weeks treatment were 83 and 97% vs. 69 and 94% in the antacid and cimetidine groups respectively. No significant differences were observed between the treatment groups regarding ulcer healing, symptom relief or compliance. Adverse reactions were few and only 3 (9%) patients in the antacid group had to discontinue the treatment due to diarrhoea. Of the cimetidine treated patients, 61% had symptomatic relapse during the 1 year follow‐up compared to 71% of the antacid treated patients. There were no significant differences in recurrence rate or time to relapse. The moderate dose antacid treatment used here is efficient, well tolerated, safe, convenient and is a good alternative treatment of the duodenal ulcer patient. 1987 Association for the Publication of the Journal of Internal Medicine

AB - ABSTRACT. Becker U, Lindorff K, Andersen C, Ranløv PJ (Department of Internal Medicine B, Central Hospital, Hillerød, Denmark). Antacid treatment of duodenal ulcer. Acta Med Scand 1987; 221:95–101. Sixty‐seven consecutive outpatients with endoscopically verified duodenal ulcer were randomised to a double‐blind treatment with either 10 ml of an antacid suspension (buffering capacity 85 mmol/10 ml, packed in single dosage pads) 1 and 3 h after each meal and at bedtime or cimetidine 400 mg b.i.d. The double‐dummy technique was employed. Endoscopy was performed after 4 weeks treatment and, if the ulcer had not healed, after 8 weeks treatment. When ulcer healing had occurred, the patient entered a 1 year follow‐up study. The cumulative healing rates after 4 and 8 weeks treatment were 83 and 97% vs. 69 and 94% in the antacid and cimetidine groups respectively. No significant differences were observed between the treatment groups regarding ulcer healing, symptom relief or compliance. Adverse reactions were few and only 3 (9%) patients in the antacid group had to discontinue the treatment due to diarrhoea. Of the cimetidine treated patients, 61% had symptomatic relapse during the 1 year follow‐up compared to 71% of the antacid treated patients. There were no significant differences in recurrence rate or time to relapse. The moderate dose antacid treatment used here is efficient, well tolerated, safe, convenient and is a good alternative treatment of the duodenal ulcer patient. 1987 Association for the Publication of the Journal of Internal Medicine

KW - antacid

KW - cimetidine

KW - duodenai ulcer

KW - healing

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=0023160112&partnerID=8YFLogxK

U2 - 10.1111/j.0954-6820.1987.tb01249.x

DO - 10.1111/j.0954-6820.1987.tb01249.x

M3 - Journal article

VL - 221

SP - 95

EP - 101

JO - ACTA MEDICA SCANDINAVICA

JF - ACTA MEDICA SCANDINAVICA

SN - 0001-6101

IS - 1

ER -

BECKER ULRIK, LINDORFF KAREN, ANDERSEN CARSTEN, RANLØV POULJØRGEN. Antacid Treatment of Duodenal Ulcer. ACTA MEDICA SCANDINAVICA. 1987 jan 1;221(1):95-101. https://doi.org/10.1111/j.0954-6820.1987.tb01249.x